Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of Neuromyelitis Optica: Review and Recommendations.

Literature DB >> 24555176

Treatment of Neuromyelitis Optica: Review and Recommendations.

Dorlan J Kimbrough¹, Kazuo Fujihara², Anu Jacob³, Marco A Lana-Peixoto⁴, Maria Isabel Leite⁵, Michael Levy¹, Romain Marignier⁶, Ichiro Nakashima², Jacqueline Palace⁵, Jérôme de Seze⁷, Olaf Stuve⁸, Silvia N Tenembaum⁹, Anthony Traboulsee¹⁰, Emmanuelle Waubant¹¹, Brian G Weinshenker¹², Dean M Wingerchuk¹³.

Abstract

Neuromyelitis optica (NMO) is an autoimmune demyelinating disease preferentially targeting the optic nerves and spinal cord. Once regarded as a variant of multiple sclerosis (MS), NMO is now recognized to be a different disease with unique pathology and immunopathogenesis that does not respond to traditional MS immunomodulators such as interferons. Preventive therapy in NMO has focused on a range of immunosuppressive medications, none of which have been validated in a rigorous randomized trial. However, multiple retrospective and a few recent prospective studies have provided evidence for the use of six medications for the prevention of NMO exacerbations: azathioprine, rituximab, mycophenolate mofetil, prednisone, methotrexate and mitoxantrone. This review provides a comprehensive analysis of each of these medications in NMO and concludes with a set of recommended consensus practices.

Entities: Chemical Disease Gene Species

Keywords: Neuromyelitis optica; aquaporin 4; drug therapy; immunosuppression

Year: 2012 PMID： 24555176 PMCID： PMC3926208 DOI： 10.1016/j.msard.2012.06.002

Source DB: PubMed Journal: Mult Scler Relat Disord ISSN： 2211-0348 Impact factor: 4.339

55 in total

1. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica.

Authors: C Costanzi; M Matiello; C F Lucchinetti; B G Weinshenker; S J Pittock; J Mandrekar; P Thapa; A McKeon
Journal: Neurology Date: 2011-08-03 Impact factor: 9.910

2. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Authors: A Kandiel; A G Fraser; B I Korelitz; C Brensinger; J D Lewis
Journal: Gut Date: 2005-08 Impact factor: 23.059

3. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.

Authors: J M Vose; B K Link; M L Grossbard; M Czuczman; A Grillo-Lopez; P Gilman; A Lowe; L A Kunkel; R I Fisher
Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544

4. Neuromyelitis optica treatment: analysis of 36 patients.

Authors: Denis Bernardi Bichuetti; Enedina Maria Lobato de Oliveira; Daniel May Oliveira; Nilton Amorin de Souza; Alberto Alain Gabbai
Journal: Arch Neurol Date: 2010-09

Review 5. Integrative continuum: accelerating therapeutic advances in rare autoimmune diseases.

Authors: Katja Van Herle; Jacinta M Behne; Andre Van Herle; Terrence F Blaschke; Terry J Smith; Michael R Yeaman
Journal: Annu Rev Pharmacol Toxicol Date: 2012 Impact factor: 13.820

6. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica.

Authors: C Papeix; J-S Vidal; J de Seze; C Pierrot-Deseilligny; A Tourbah; B Stankoff; C Lebrun; T Moreau; P Vermersch; B Fontaine; O Lyon-Caen; O Gout
Journal: Mult Scler Date: 2007-01-29 Impact factor: 6.312

7. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica.

Authors: S Watanabe; I Nakashima; T Misu; I Miyazawa; Y Shiga; K Fujihara; Y Itoyama
Journal: Mult Scler Date: 2007-01 Impact factor: 6.312

8. Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG).

Authors: Jacqueline Bakker; Luanne Metz
Journal: Can J Neurol Sci Date: 2004-05 Impact factor: 2.104

9. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.

Authors: Anu Jacob; Brian G Weinshenker; Ivo Violich; Nancy McLinskey; Lauren Krupp; Robert J Fox; Dean M Wingerchuk; Mike Boggild; Cris S Constantinescu; Aaron Miller; Tracy De Angelis; Marcelo Matiello; Bruce A C Cree
Journal: Arch Neurol Date: 2008-09-08

10. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.

Authors: Vanda A Lennon; Thomas J Kryzer; Sean J Pittock; A S Verkman; Shannon R Hinson
Journal: J Exp Med Date: 2005-08-08 Impact factor: 14.307

68 in total

Review 1. Neuroinflammation: Ways in Which the Immune System Affects the Brain.

Authors: Richard M Ransohoff; Dorothy Schafer; Angela Vincent; Nathalie E Blachère; Amit Bar-Or
Journal: Neurotherapeutics Date: 2015-10 Impact factor: 7.620

Review 2. Neuromyelitis optica spectrum disorders associated with other autoimmune diseases.

Authors: Eduardo Freitas; Joana Guimarães
Journal: Rheumatol Int Date: 2014-06-22 Impact factor: 2.631

3. "A rose by any other name": does defining extreme phenotypes add to the management of multiple sclerosis?

Authors: Evan A Jolliffe; Brian G Weinshenker
Journal: Ann Transl Med Date: 2018-10

Review 4. Longitudinally extensive myelopathy in children.

Authors: Danielle Eckart Sorte; Andrea Poretti; Scott D Newsome; Eugen Boltshauser; Thierry A G M Huisman; Izlem Izbudak
Journal: Pediatr Radiol Date: 2015-01-31

Review 5. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors: Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal: Nat Rev Neurol Date: 2014-08-12 Impact factor: 42.937

6. Comprehensive analysis of patients with neuromyelitis optica spectrum disorder (NMOSD) combined with chronic hepatitis B (CHB) infection and seropositive for anti-aquaporin-4 antibody.

Authors: Jia Liu; Li Xu; Zhuo-Lin Chen; Min Li; Huan Yi; Fu-Hua Peng
Journal: Bosn J Basic Med Sci Date: 2018-02-20 Impact factor: 3.363